CEL-SCI Corp SEC Filings

CEL-SCI Corporation amended its Shareholder Rights Agreement, setting a new expiration of October 30, 2030. The agreement was originally adopted on November 7, 2007. The company filed the amended agreement as an exhibit and referenced the summary in its prior Form S-3 under “Description of Securities - Rights Agreement.”

Form 4 filed for CEL-SCI Corp (CVM) discloses that the reporting person, identified as an officer with the title Chief Scientific Officer, executed a purchase on 09/30/2025. The report shows an acquisition of 260 shares of Common Stock at a price of $9.20 per share, resulting in 5,808 shares beneficially owned following the transaction. The Form is signed by the reporting person on 10/02/2025.

Patricia Prichep, Chief Financial Officer of CEL-SCI Corporation (CVM), reported an open-market purchase of company common stock. On 09/30/2025 she acquired 466 shares at a reported price of $9.20 per share. After this transaction she beneficially owns 11,213 shares directly. The filing is a Form 4 statement of changes in beneficial ownership and is signed by Ms. Prichep on 10/02/2025. The report identifies her relationship to the issuer as an officer with the title Chief Financial Officer.

Geert Kersten, listed as Chief Executive Officer and a director of CEL-SCI Corporation (CVM), reported an open-market purchase of 570 shares of CEL-SCI common stock on 09/30/2025 at a price of $9.20 per share. After this transaction the filing shows 73,405 shares beneficially owned directly. The Form 4 was signed on 10/02/2025. The report contains no derivative transactions and includes no additional explanatory disclosures.

Lincoln Alternative Strategies LLC reported beneficial ownership of 555,000 shares of CEL-SCI Corporation common stock, representing 6.94% of the outstanding class. The filing states the reporter is organized in Delaware and holds sole voting and dispositive power over these shares. The report also includes a certification that the shares were not acquired to change or influence control of the issuer and are not held in connection with such transactions. The disclosure identifies the position as passive ownership under the Schedule 13G framework and provides the reporter's signature by its managing member.

Cel-Sci (CVM) prospectus supplement excerpt reports clinical outcomes from a trial with dates noted: June 30, 2025 and August 22, 2025. The results state no lymph node involvement by PET imaging and low PD-L1 tumor expression (TPS <10) on biopsy. Treated patients showed a 0.349 hazard ratio for death versus control (95% CI [0.18, 0.66], Wald p=0.0012), representing a 28.6% absolute 5-year overall survival benefit versus control (p=0.0015) and a stated risk-of-death reduction of about one-half at five years. The data also report greater than 35% rates of pre-surgery tumor reductions and/or downstages (p<0.01). The excerpt contrasts the low PD-L1 context with settings where Keytruda and Opdivo work best (high PD-L1).

Cel-Sci Corporation (CVM) prospectus supplement excerpt highlights clinical and securities details. The text states the company’s product candidates are intended to be given immediately after diagnosis and before any other treatment, including surgery. Clinical outcomes cited include a reduction in risk of death by half at five years versus control, a 28.6% absolute 5-year overall survival benefit (p=0.0015), and a hazard ratio of 0.349 versus control with 95% CIs [0.18, 0.66] (Wald p=0.0012). The excerpt also reports a >35% rate of pre-surgery tumor reductions and/or downstages (p<0.01) and notes activity in tumors with low PD-L1 expression (TPS <10), where some checkpoint inhibitors are less effective.

The filing excerpt discloses that 546,894 shares of common stock are issuable upon exercise of outstanding stock options as of June 30, 2025, at a weighted average exercise price of $195.06 per share. The text includes dates (June 30, 2025; August 22, 2025) and a Bloomberg market reference link but does not provide offering size, proceeds, or complete prospectus financial tables in this excerpt.